We investigated the effect of changes to state AIDS Drug Assistance Programs (ADAP) policies, which govern access to antiretroviral therapy (ART), on clinical and economic outcomes among low-income people living with HIV/AIDS. Retrospective analyses of ART access were conducted on state ADAP policies, using data from ADAP Monitoring Reports and Kaiser Family Foundation from 2006 to 2010. We found stricter eligibility requirements reduce the number of HIV-positive individuals with ART access through ADAP, and decreased ART use increases mortality by 2.67 quality-adjusted life years (QALYs) per beneficiary. If the ADAP income eligibility cutoff were decreased by 50 percentage points in each state, 4,626 individuals would lose ART access nationwide. Based on a $22,143 cost/QALY, this policy would save $274 million in health care expenditures (2012 dollars), but result in 12,352 QALYs lost, valued at $1.2 billion. Therefore, states should exercise caution in restricting programs that increase ART access for low-income people living with HIV/AIDS.
American Academy of HIV Medicine. (2014). The Affordable Care Act: One year later. HIV Specialist Magazine. Retrieved from http://www.aahivm.org/hivspecialist
BernellS. L.ShinogleJ. A. (2005). The relationship between HAART use and employment for HIV-positive individuals: An empirical analysis and policy outlook. Health Policy, 71, 255-264.
5.
BhattacharyaJ.GoldmanD.SoodN. (2003). The link between public and private insurance and HIV-related mortality. Journal of Health Economics, 22, 1105-1122.
6.
BraithwaiteR. S.MeltzerD. O.KingJ. T.Jr.LeslieD.RobertsM. S. (2008). What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Medical Care, 46, 349-356.
BroganA. J.TalbirdS. E.CohenC. (2011). Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States. Value in Health: The journal of the International Society for Pharmacoeconomics and Outcomes Research, 14, 657-664.
9.
BrownJ. R.FinkelsteinA. (2008). The interaction of public and private insurance: Medicaid and the long-term care insurance market. American Economic Review, 98, 1083-1102.
10.
Bureau of Labor Statistics. (2012). Consumer price index. Retrieved from http://www.bls.gov/cpi/
11.
CardD.Shore-SheppardL. D. (2004). Using discontinuous eligibility rules to identify the effects of the federal Medicaid expansions on low-income children. Review of Economics and Statistics, 86, 752-766.
CohenM. S.ChenY. Q.McCauleyM.GambleT.HosseinipourM. C.KumarasamyN.. . .FlemingT. R. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine, 365, 493-505.
CutlerD. M.GruberJ. (1996). Does public insurance crowd out private insurance?Quarterly Journal of Economics, 111, 391-430.
20.
CutlerD. M.RichardsonE.KeelerT. E.StaigerD. (1997). Measuring the health of the US population. Brookings Papers on Economic Activity. Microeconomics, 1997, 217-282.
21.
CutlerD. M.RosenA. B.VijanS. (2006). The value of medical spending in the United States, 1960-2000. New England Journal of Medicine, 355, 920-927.
22.
DetelsR.MuñozA.McFarlaneG.KingsleyL. A.MargolickJ. B.GiorgiJ.. . .PhairJ. P. (1998). Effectiveness of potent antiretroviral therapy on time to aids and death in men with known HIV infection duration. Journal of the American Medical Association, 280, 1497-1503.
23.
DoshiR. K.MilbergJ.IsenbergD.MatthewsT.MalitzF.MatoskyM.. . .CheeverL. W. (2015). High rates of retention and viral suppression in the US HIV safety net system: HIV care continuum in the Ryan White HIV/AIDS Program, 2011. Clinical Infectious Disease, 60, 117-125. doi:10.1093/cid/ciu722
24.
El-SadrW. M.LundgrenJ.NeatonJ. D.GordinF.AbramsD.ArduinoR. C.. . .RappoportC. (2006). CD4+ count-guided interruption of antiretroviral treatment. New England Journal of Medicine, 355, 2283-2296.
25.
FernandezB.GabeT. (2013). Health insurance premium credits in the Patient Protection and Affordable Care Act (ACA). Retrieved from https://www.fas.org/sgp/crs/misc/R41137.pdf
26.
FreedbergK. A.LosinaE.WeinsteinM. C.PaltielA. D.CohenC. J.SeageG. R.. . .GoldieS. J. (2001). The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine, 344, 824-831.
27.
GodwinN. C.WilligJ. H.NevinC. R.LinH. Y.AllisonJ.GaddisK.. . .RaperJ. L. (2011). Underutilization of the AIDS Drug Assistance Program: Associated factors and policy implications. Health Services Research, 46, 982-995.
28.
GoldmanD. P.BaoY. (2004). Effective HIV treatment and the employment of HIV+ adults. Health Services Research, 39(6 Pt 1), 1691-1712.
29.
GoldmanD. P.BhattacharyaJ.LeibowitzA. A.JoyceG. F.ShapiroM. F.BozzetteS. A. (2001). The impact of state policy on the costs of HIV infection. Medical Care Research and Review, 58, 31-53.
30.
GoldmanD. P.LeibowitzA. A.JoyceG. F.FleishmanJ. A.BozzetteS. A.DuanN.ShapiroM. F. (2003). Insurance status of HIV-infected adults in the post-HAART era: Evidence from the United States. Applied Health Economics and Health Policy, 2, 85-90.
31.
GopalappaC.FarnhamP. G.HutchinsonA. B.SansomS. L. (2012). Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes, 61, 99-105.
32.
GrimesR. M.ShenoudaT. A. (2013). Using cost as a consideration for antiretroviral regimen selection: An example using average wholesale prices. AIDS Care, 25, 1380-1384.
33.
GruberJ.SimonK. (2008). Crowd-out 10 years later: Have recent public insurance expansions crowded out private health insurance?Journal of Health Economics, 27, 201-217.
34.
HannaD. B.BuchaczK.GeboK. A.HessolN. A.HorbergM. A.JacobsonL. P.. . .GangeS. J. (2013). Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One, 8, e78952. doi:10.1371/journal.pone.0078952
HirthR. A.ChernewM. E.MillerE.FendrickA. M.WeissertW. G. (2000). Willingness to pay for a quality-adjusted life year: In search of a standard. Medical Decision Making, 20, 332-342.
37.
JulgB.GoebelF. D. (2006). Treatment interruption in HIV therapy: A SMART strategy?Infection, 34, 186-188.
KatesJ.GarfieldR.YoungK.QuinnK.FrazierE.SkarbinskiJ. (2014). Assessing the impact of the Affordable Care Act on health insurance coverage of people with HIV. Menlo Park, CA: Kaiser Family Foundation.
KitahataM. M.GangeS. J.AbrahamA. G.MerrimanB.SaagM. S.JusticeA. C.. . .MooreR. D. (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of Medicine, 360, 1815-1826.
46.
KuhnL.AldrovandiG. M.SinkalaM.KankasaC.MwiyaM.TheaD. M. (2010). Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to-child HIV transmission. AIDS, 24, 1374-1377.
47.
MartinE. G.WangK. H. (2013). Integrating substance abuse treatment into HIV care: Missed opportunities in the AIDS Drug Assistance Program. Journal of Acquired Immune Deficiency Syndromes, 62, 421-429.
48.
MauskopfJ. (2013). A methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection. Pharmacoeconomics, 31, 1031-1050.
49.
McManusK. A.EngelhardC. L.DillinghamR. (2013). Current challenges to the United States’ AIDS drug assistance program and possible implications of the Affordable Care Act. AIDS Research and Treatment, 2013, 350169.
50.
McManusK. A.PinkertonR.DillinghamR. (2014). Effects of recent Virginia AIDS Drug Assistance Program policy changes on diabetes and hyperlipidemia control in people living with HIV. SAGE Open Medicine, 2, 2050312114532809.
51.
National Alliance of State & Territorial AIDS Directors. (2012). National ADAP Monitoring Project annual report.
52.
OlsonK. M.GodwinN. C.WilkinsS. A.MugaveroM. J.MoneyhamL. D.SlaterL. Z.RaperJ. L. (2014). A qualitative study of underutilization of the AIDS drug assistance program. Journal of the Association of Nurses in AIDS Care, 25, 392-404. doi:10.1016/j.jana.2013.11.003
Patient Protection and Affordable Care Act. (2010). 42 U.S.C. § 18001.
55.
PinkertonS. D.KibichoJ.GalletlyC. L. (2013). Is the US AIDS drug assistance program cost-effective?AIDS and Behavior, 17(1), 1-4.
56.
PriceC. C.EibnerC. (2013). For states that opt out of Medicaid expansion: 3.6 million fewer insured and $8.4 billion less in federal payments. Health Affairs, 32, 1030-1036.
57.
RomleyJ.JudayT.SolomonM.SeekinsD.BrookmeyerR.GoldmanD. (2014). Early HIV treatment led to life expectancy gains valued at $80 billion for persons infected between 1996 and 2009. Health Affairs, 33, 370-377.
58.
SniderJ. T.JudayT.RomleyJ.SeekinsD.RosenblattL.GoldmanD. P. (2014). Nearly 60,000 uninsured, low-income people with HIV/AIDS live in states that are not moving forward with Medicaid expansion under the Affordable Care Act. Health Affairs, 33, 386-393.
59.
SpragueC.SimonS. E. (2014). Understanding HIV care delays in the US South and the role of the social-level in HIV care engagement/retention: A qualitative study. International Journal for Equity in Health, 13, 28.
60.
StaszewskiS.Morales-RamirezJ.TashimaK. T.RachlisA.SkiestD.StanfordJ.. . .RuizN. M. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine, 341, 1865-1873.
61.
TennantS. J.HesterE. K.CaulderC. R.LuZ. K.BookstaverP. B. (2015). Adherence among rural HIV-infected patients in the Deep South: A comparison between single-tablet and multi-tablet once-daily regimens. Journal of the International Association of Providers of AIDS Care, 14(1), 64-71.
UbelP. A.HirthR. A.ChernewM. E.FendrickA. M. (2003). What is the price of life and why doesn’t it increase at the rate of inflation?Archives of Internal Medicine, 163, 1637-1641.
64.
ViscusiW. K.AldyJ. E. (2003). The value of a statistical life: A critical review of market estimates throughout the world. Journal of Risk and Uncertainty, 27(1), 5-76.
65.
WalenskyR. P.SaxP. E.NakamuraY. M.WeinsteinM. C.PeiP. P.FreedbergK. A.. . .SchackmanB. R. (2013). Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States. Annals of Internal Medicine, 158(2), 84-92.
66.
YaziciE. Y.KaestnerR. (1998). Medicaid expansions and the crowding out of private health insurance. Cambridge, MA: National Bureau of Economic Research.
67.
YiT.CocohobaJ.CohenM.AnastosK.DeHovitzJ. A.KonoN.. . .HessolN. A. (2011). The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. Journal of Acquired Immune Deficiency Syndromes, 56, 253-262.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
